Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

@article{Stangier2005PharmacokineticPO,
  title={Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement},
  author={J. Stangier and B. Eriksson and O. Dahl and L. Ahnfelt and G. Nehmiz and H. Staehle and K. Rathgen and R. Sv{\"a}rd},
  journal={The Journal of Clinical Pharmacology},
  year={2005},
  volume={45}
}
  • J. Stangier, B. Eriksson, +5 authors R. Svärd
  • Published 2005
  • Medicine
  • The Journal of Clinical Pharmacology
  • Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its active form, dabigatran. The authors investigated the absorption, distribution, and elimination of a single 150‐mg dose capsule formulation of dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. In an open‐label, 3‐way crossover study, dabigatran etexilate was administered to 18 male volunteers in… CONTINUE READING
    264 Citations
    Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
    • J. Stangier, A. Clemens
    • Medicine
    • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    • 2009
    • 287
    Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    • M. L. Blommel, A. L. Blommel
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2011
    • 70
    • PDF
    Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
    • 98
    An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis
    • 20

    References

    SHOWING 1-10 OF 23 REFERENCES
    Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
    • 207
    Management of venous thromboembolism: past, present, and future.
    • T. Hyers
    • Medicine
    • Archives of internal medicine
    • 2003
    • 85
    • PDF